Get the Stockscreener App
3.65
8.29%
-0.33
After Hours:
3.67
0.02
+0.55%
Perspective Therapeutics Inc stock is traded at $3.65, with a volume of 2.97M.
It is down -8.29% in the last 24 hours and down -17.23% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$3.98
Open:
$3.99
24h Volume:
2.97M
Relative Volume:
1.39
Market Cap:
$416.16M
Revenue:
$884.00K
Net Income/Loss:
$-103.64M
P/E Ratio:
-2.6176
EPS:
-1.3944
Net Cash Flow:
$-95.45M
1W Performance:
-7.59%
1M Performance:
-17.23%
6M Performance:
+56.65%
1Y Performance:
+50.21%
1-Day Range:
$3.60
$4.08
1-Week Range:
$3.60
$4.10
52-Week Range:
$1.955
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
3.65 | 453.79M | 884.00K | -103.64M | -95.45M | -1.3944 |
ABT
Abbott Laboratories
|
87.17 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | Piper Sandler | Overweight |
| Nov-24-25 | Resumed | Truist | Buy |
| Oct-10-25 | Initiated | BTIG Research | Buy |
| Mar-13-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-01-24 | Initiated | Wedbush | Outperform |
| Sep-25-24 | Initiated | Truist | Buy |
| Jul-25-24 | Initiated | BofA Securities | Buy |
| May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
Perspective Therapeutics Advances 212Pb Radioligand Therapy for Targeted Oncology with Regional Manufacturing and Theranostic Approach 1245 - Minichart
Perspective Therapeutics, Inc. (CATX) Shareholder/Analyst CallSlideshow (NYSE:CATX) 2026-05-04 - Seeking Alpha
Perspective Therapeutics (CATX) unveils 212Pb theranostic pipeline and manufacturing strategy - Stock Titan
Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field - Seeking Alpha
BlackRock stake in Perspective Therapeutics (CATX): 5.25M shares - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Tarsus Pharmaceuticals (TARS), Perspective Therapeutics (CATX) - The Globe and Mail
Perspective Therapeutics to Provide Several Upcoming Corporate Updates - The Manila Times
Perspective Therapeutics, Inc. to Provide Corporate Updates and Financial Results in May 2026 - Quiver Quantitative
Perspective Therapeutics maps out May updates, Q1 results on May 11 - Stock Titan
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Perspective Therapeutics (CATX) and UnitedHealth (UNH) - The Globe and Mail
CATX (Perspective Therapeutics Inc.) slips 1.41% after reporting Q4 2025 EPS that misses analyst estimates by 40.3%.Stock Community Signals - Cổng thông tin điện tử tỉnh Tây Ninh
CATX Technical Analysis | Trend, Signals & Chart Patterns | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
Analysts’ Top Healthcare Picks: Perspective Therapeutics (CATX), Nektar Therapeutics (NKTR) - The Globe and Mail
JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Analysts Offer Insights on Healthcare Companies: Immatics (IMTX), Incyte (INCY) and Perspective Therapeutics (CATX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), Centessa Pharmaceuticals (CNTA) and Perspective Therapeutics (CATX) - The Globe and Mail
Perspective Therapeutics reports interim trial results for NET therapy By Investing.com - Investing.com India
Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsight - GlobeNewswire Inc.
CATX Reiterates by Wedbush -- Price Target Maintained at $11 - GuruFocus
Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Gap UpShould You Buy? - MarketBeat
[212Pb]VMT-α-NET Shows Promising Safety and Efficacy in Advanced Neuroendocrine Tumor Phase I/IIa Trial (Data Cutoff March 2026) - Minichart
Perspective Therapeutics (CATX) Updates Clinical Trial Results f - GuruFocus
Wedbush Reaffirms Outperform Rating for Perspective Therapeutics (NYSEAMERICAN:CATX) - MarketBeat
Perspective Therapeutics reports interim trial results for NET therapy - Investing.com
Perspective Therapeutics Provides Updated Interim Results From Phase 1/2a Cancer Trial - marketscreener.com
Perspective Therapeutics Highlights Encouraging Interim Neuroendocrine Tumor Data - TipRanks
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting - The Manila Times
Perspective Therapeutics posts updated Phase 1/2a [212Pb]VMT-α-NET data showing 43% response in Cohort 2 - TradingView
[8-K] Perspective Therapeutics, Inc. Reports Material Event - Stock Titan
EBITDA per share of Perspective Therapeutics, Inc. – FWB:AAJ0 - TradingView
Perspective Therapeutics (NASDAQ: CATX) sets 2026 director, auditor and pay vote - Stock Titan
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Sees Large Increase in Short Interest - MarketBeat
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Perspective Therapeutics Inc. R (AAJ0.DU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
JPMorgan Chase & Co. Sells 311,710 Shares of Perspective Therapeutics, Inc. $CATX - MarketBeat
CATX Stock Price, Quote & Chart | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
PERSPECTIVE THERAPEUTICS INC (CATX) Fundamental Analysis & Valuation - ChartMill
Perspective Therapeutics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Perspective Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Perspective Therapeutics Advances First-in-Class 212Pb Radiopharmaceuticals for Solid Tumor Oncology Treatment - Minichart
Perspective Therapeutics Highlights Progress in 212Pb Oncology Pipeline - TipRanks
Perspective Therapeutics updates corporate presentation, expects Phase 1/2 data across three programs in 2026 - TradingView — Track All Markets
Perspective Therapeutics (NYSE: CATX) spotlights 212Pb radiopharmaceutical cancer pipeline - Stock Titan
Revenue Check: Can Perspective Therapeutics Inc grow without dilution2026 Sentiment & Proven Capital Preservation Methods - baoquankhu1.vn
CATX Rallies on Merger News - UBND thành phố Hải Phòng
Analyst Upgrade: Can Perspective Therapeutics Inc expand into new marketsRisk Management & Weekly Hot Stock Watchlists - baoquankhu1.vn
Aug Analyst Calls: What is the next catalyst for Perspective Therapeutics IncGlobal Markets & Advanced Technical Analysis Signals - baoquankhu1.vn
Perspective Therapeutics Q1 EPS Raised by HC Wainwright - MarketBeat
Investment Recap: What is the next catalyst for Perspective Therapeutics IncMarket Growth Report & Risk Controlled Daily Plans - baoquankhu1.vn
H.C. Wainwright raises Perspective Therapeutics price target to $13 By Investing.com - Investing.com South Africa
CATX: HC Wainwright & Co. Raises Price Target to $13, Maintains Buy Rating | CATX Stock News - GuruFocus
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.93%
Cap:
|
Volume (24h):